Welcome to our dedicated page for Livanova Plc SEC filings (Ticker: LIVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. SEC filings for LivaNova PLC (NASDAQ: LIVN), a global medical technology company headquartered in London and incorporated in England and Wales. As a foreign private issuer with securities listed in the United States, LivaNova files reports with the Securities and Exchange Commission that document material events, financial results, and corporate governance changes.
Among the filings available are Form 8‑K current reports, which LivaNova uses to announce items such as quarterly financial results, business update conference calls, and board appointments. For example, the company has filed 8‑K reports to furnish press releases on results for quarters ended June 30 and September 30, and to disclose the appointment of a new director to its Board and Audit and Compliance Committee.
Investors and analysts can also use this page to locate LivaNova’s annual and periodic reports, which typically include information on its Epilepsy and Cardiopulmonary businesses, neuromodulation therapies such as VNS Therapy, and its global operations in neurological and cardiac conditions. These documents can help readers understand segment performance, risk factors, and other disclosures that complement the company’s press releases.
Stock Titan enhances these filings with AI‑powered summaries that explain the key points of lengthy documents, such as earnings releases or other detailed reports. Real‑time updates from the EDGAR system ensure that new LivaNova filings appear promptly, while AI highlights important sections so users can quickly see what changed, which items are being furnished rather than filed, and how corporate events may relate to LIVN stock.
Users interested in governance and oversight can review filings that describe board composition and committee membership. Those focused on financial performance can concentrate on filings that furnish earnings press releases and related metrics.
LivaNova PLC’s ownership report shows several Millennium-affiliated entities holding more than five percent of its ordinary shares as of December 31, 2025. Integrated Core Strategies (US) LLC reports beneficial ownership of 3,065,717 shares, representing 5.6% of the class.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 3,484,082 shares, or 6.4% of the outstanding ordinary shares, through entities over which they have voting control and investment discretion. They certify the holdings are not for the purpose of changing or influencing control of LivaNova.
LivaNova PLC reported a leadership change in its legal function. On January 12, 2026, Senior Vice President, Chief Legal Officer, and Company Secretary Michael Hutchinson notified the company that he is resigning to pursue another opportunity. His last day with LivaNova will be January 26, 2026, creating a near-term transition period for the company’s legal and governance roles.
The company plans to retain an external search firm to begin the process of finding a new Chief Legal Officer, indicating that the board and management aim to bring in a successor through a structured, formal search.
LivaNova PLC officer reports RSU vesting and share withholding for taxes. The President, Cardiopulmonary of LivaNova PLC reported the vesting and settlement of 967 restricted stock units into ordinary shares on 12/15/2025 at an exercise price of $0. On the same date, 416 ordinary shares were disposed of through share withholding at a price of $63.06 to satisfy tax liabilities related to the vesting.
After these transactions, the officer beneficially owns 8,850 ordinary shares directly and 219 ordinary shares indirectly through a spouse. The RSUs were originally granted on December 15, 2023 under the Amended and Restated LivaNova PLC 2022 Incentive Award Plan and vested over a two-year schedule ending December 15, 2025.
LivaNova PLC director reported share activity related to vested restricted stock units. On December 15, 2025, 2,355 ordinary shares were acquired at $0 upon the exercise of previously granted RSUs under the LivaNova PLC 2015 Incentive Award Plan. On the same date, 269 shares were disposed of at $63.06 to cover tax liabilities, leaving 2,086 ordinary shares beneficially owned directly after these transactions.
The RSUs were originally granted on December 15, 2024 with a one-year vesting schedule and were subject to forfeiture before vesting under the plan and award agreement.
LivaNova PLC senior vice president, chief legal officer and company secretary reported routine equity activity related to restricted stock units. On December 15, 2025, 2,254 RSUs vested and were settled in ordinary shares at an exercise price of $0, increasing her directly held stake. On the same date, 1,122 ordinary shares were withheld at $63.06 per share to cover tax obligations, leaving 6,798 ordinary shares held directly after the transactions. The underlying RSUs were originally granted on December 15, 2022, under the LivaNova PLC 2022 Incentive Award Plan with a four-year vesting schedule, and 2,253 RSUs remain beneficially owned following this vesting event.
LivaNova PLC director reports small share sale in Form 4 filing. A company director sold 250 ordinary shares of LivaNova PLC (LIVN) on 11/18/2025 at a price of $53.94 per share. After this transaction, the director beneficially owns 6,232 ordinary shares, held directly. This filing is a routine disclosure of insider activity required under securities regulations and does not by itself describe any change in the company’s operations or strategy.
LivaNova PLC reported stronger Q3 2025 results. Net revenue rose to $357.8 million from $318.1 million, with operating income of $54.0 million and net income of $26.8 million ($0.49 diluted). For the first nine months, the company posted a net loss of $273.4 million, primarily driven by the $363.8 million SNIA environmental liability expense booked earlier in the year.
Cash and cash equivalents were $646.1 million, aided by operating cash flow of $171.9 million year-to-date. LivaNova repaid $200 million on its Term Facilities in May, reducing long-term debt to $349.0 million. The company recorded a current liability of $394.6 million (€336.3 million) related to the SNIA matter, reflecting its best estimate including costs, fees, interest, and taxes.
On the cybersecurity incident disclosed in 2023, cumulative direct costs totaled $13.1 million through September 30, 2025, and insurance reimbursements received totaled $9.6 million. Ordinary shares outstanding were 54,605,527 as of October 29, 2025.
LivaNova PLC furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The company will host a business update conference call and webcast on November 5, 2025, at 1 p.m. London time (8 a.m. Eastern Time), accessible via its events page.
The related press release is attached as Exhibit 99.1 and, under Item 2.02, is being furnished and not deemed filed under the Exchange Act.
LivaNova PLC (LIVN) director Donald Zurbay was granted 2,560 Restricted Stock Units (RSUs) on September 15, 2025. Each RSU converts to one ordinary share under the LivaNova PLC 2025 Director Incentive Award Plan. The grant carries vesting and forfeiture restrictions that are scheduled to lapse on June 15, 2026, subject to continued service and the award agreement. The reported RSUs have a $0 per-unit reported grant price on the Form 4 and are shown as directly beneficially owned following the award. The Form 4 was signed on behalf of the reporting person by an Attorney-in-Fact on September 17, 2025.
FAQ
What is the current stock price of Livanova Plc (LIVN)?
What is the market cap of Livanova Plc (LIVN)?
